References
- Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N. Engl. J. Med.348(17), 1681–1691 (2003).
- Ramsay HM, Reece SM, Fryer AA, Smith AG, Harden PN. Seven-year prospective study of nonmelanoma skin cancer incidence in U.K. renal transplant recipients. Transplantation84(3), 437–439 (2007).
- Berg D, Otley CC. Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management. J. Am. Acad. Dermatol.47(1), 1–17; quiz 18–20 (2002).
- Jorizzo JL. Current and novel treatment options for actinic keratosis. J. Cutan. Med. Surg.8(Suppl. 3), 13–21 (2004).
- Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr. Opin. Immunol.19(2), 203–208 (2007).
- Carroll RP, Segundo DS, Hollowood K et al. Immune phenotype predicts risk for posttransplantation squamous cell carcinoma. J. Am. Soc. Nephrol.21, 713–722 (2010).
- Klonowski KD, Marzo AL, Williams KJ, Lee SJ, Pham QM, Lefrancois L. CD8 T cell recall responses are regulated by the tissue tropism of the memory cell and pathogen. J. Immunol.177(10), 6738–6746 (2006).
- Muehleisen B, Schaerer L, Dummer R, Burg G, Hofbauer GF. Cancer/testis antigen MAGE-A4 expression pattern differs in epithelial skin tumors of organ-transplant recipients and immunocompetent patients. J. Cutan. Pathol.34(1), 1–6 (2007).
- Muhleisen B, Petrov I, Gachter T et al. Progression of cutaneous squamous cell carcinoma in immunosuppressed patients is associated with reduced CD123+ and FOXP3+ cells in the perineoplastic inflammatory infiltrate. Histopathology55(1), 67–76 (2009).
- Kosmidis M, Dziunycz P, Suarez-Farinas M et al. Immunosuppression affects CD4+ mRNA expression and induces Th2 dominance in the microenvironment of cutaneous squamous cell carcinoma in organ transplant recipients. J. Immunother. (In Press) (2010).